We identify early signals from sources such as arXiv, Medium, and leading science journals (including Nature and Stanford/MIT), going beyond traditional finance media and broker reports, with GenAI integrated into our processes as an independent research team.

We wear our views on our sleeves through our openly available GenInnov articles, as dialogue is both valuable and intrinsic to our investment process; writing helps us refine and crystallise our thinking while enabling us to connect with and learn from domain experts and industry leaders.

We require profitability, capital discipline, and IP defensibility—innovation must be monetizable—while focusing on innovation signals rather than legacy corporate cycles, and balancing valuation comfort with potential catalysts arising from innovation efforts.

We size positions based on thesis strength and risk, constructing the portfolio bottom-up around innovation rather than benchmark allocations.